However, due to the comparatively low sensitivity of the traditional enzyme-linked immunosorbent assay (ELISA) and low concentration of NFL in the biofluid, especially in the blood, NFL assessments and their clinical application as a biomarker for ALS have been hindered in the past (15). This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.